TABLE 1.
Baseline* | |
---|---|
Median age, years (IQR) | 5.9 (2.7–9.8) |
Age [n (%)] | |
<1 | 63 (8.0) |
1–4 | 277 (35.1) |
5–9 | 265 (33.5) |
10–17 | 185 (23.4) |
Female sex [n (%)] | 415 (52.5) |
WHO HIV clinical stage [n (%)] | |
1 | 153 (19.4) |
2 | 232 (29.4) |
3 | 369 (46.7) |
4 | 36 (4.6) |
Median CD4 percentage (IQR) | 15 (9–22) |
WHO age-specific severity of immunodeficiency [n (%)] | |
Not significant | 174 (22.0) |
Mild | 88 (11.1) |
Advanced | 76 (9.6) |
Severe | 452 (57.2) |
Started cotrimoxazole at first visit [n (%)] | 726 (91.9) |
Follow-up (all children) | |
Total person-years accrued | 2089.8 |
Median months of follow-up (IQR) | 31.2 (10.3–53.6) |
Median number of program visits (IQR) | 30 (11–57) |
Died [n (%)] | 80 (10.1) |
Lost to follow-up [n (%)] | 76 (9.6) |
Transferred care [n (%)] | 6 (0.8) |
Initiated cART | 619 (78.4) |
Number of CD4 percentage results | 3137 |
Follow-up (children initiating cART) | |
Median weeks of follow-up prior to cART initiation (IQR) | 4.0 (2.2–15.3) |
Severe immunodeficiency at cART initiation [n (%)] | 454 (73.3) |
Median CD4 percentage at cART initiation (IQR) | 12 (7–18) |
cART person-years accrued | 1620.9 |
Median months on cART (IQR) | 31.3 (11.4–52.0) |
Switched cART regimen [n (%)] | 110 (17.8) |
Number of CD4 percentage results during cART | 2485 |
Baseline (first CD4 percentage result) was not at program enrollment for 41 of 790 children (5.2%). For these 41 children, the median number of months between enrollment and first CD4 percentage result was 2.3 (IQR, 1.1–5.3).